7 results
The main objective of this study is to evaluate the safety and efficacy of ABBV-105, upadacitinib, and ABBV-599 versus placebo for the treatment of signs and symptoms of SLE in participants with moderately to severely active SLE and to define doses…
The main objective of this pilot study is to investigate the feasibility of fluorescence imaging with the fluorescence agent bevacizumab-800CW to detect endometriosis tissue.
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.
Primary Objectives:To determine the optimal dose of the VEGF-targeting optical agent Bevacizumab-IRDye800CW for an adequate tumor-tobackgroundratio (TBR) during white-light (WL) / fluorescence-guided (FG) diagnostic laparoscopy (WL/FG-DLS) in…
To determine the safety and feasibility of fluorescence imaging of the eye vascularization with the fluorescent tracer bevacizumab-800CW for identification of neovascular Age-related Macular Degeneration (AMD) with scanning laser angiography.
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Primary:To evaluate the performance of FME with topical administration of Bevacizumab-800CW for detection of neoplasia in BE patients compared to HD-WLE to make an estimation of the diagnostic accuracy in terms of sensitivity and specificity in…